ABBOTT LABORATORIES vs REGENERON PHARMACEUTICALS, INC., two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Abbott and Regeneron are both drug-sector names but opposite in shape, one a diversified device-and-diagnostics company, the other a focused biotech. Regeneron keeps the far higher net margin, 30% to Abbott's 14, the economics of a small set of blockbuster drugs, and runs nearly debt-free. Their returns on equity sit close, near 12 to 14%. Regeneron is the cheaper of the two, near 15 times earnings to Abbott's 25, the discount the market attaches to concentration and patent risk. Abbott pays a 2.7% dividend Regeneron does not. Broad and steady on Abbott's side, concentrated and higher-margin on Regeneron's.
Comparison updated 2026-06-11.
| Metric | ABT | REGN |
|---|---|---|
| Price | $93.93 | $664.56 |
| Market cap | $164.1B | $71.6B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | +9.6% | +8.8% |
| P/E | 26.3 | 16.2 |
| P/B | 3.11 | 2.28 |
| P/S | 3.64 | 4.80 |
| EV/EBITDA | 20.8 | 18.8 |
| Revenue growth | +6.6% | +6.5% |
| Operating margin | 12.1% | 17.8% |
| Net margin | 13.9% | 29.6% |
| Return on equity | 11.9% | 14.1% |
| Return on assets | 5.7% | 10.8% |
| Return on invested capital | 6.6% | 9.5% |
| FCF yield | 4.5% | 5.8% |
| Dividend yield | 2.6% | — |
| Debt / equity | 0.65 | 0.06 |
| Current ratio | 1.39 | 3.57 |
| Altman Z (solvency) | 7.16 | 6.60 |
| Piotroski F (quality) | 6 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.